CY1121012T1 - Ταπενταδολη για την προληψη της χρονιοποιησης του πονου - Google Patents

Ταπενταδολη για την προληψη της χρονιοποιησης του πονου

Info

Publication number
CY1121012T1
CY1121012T1 CY181101327T CY181101327T CY1121012T1 CY 1121012 T1 CY1121012 T1 CY 1121012T1 CY 181101327 T CY181101327 T CY 181101327T CY 181101327 T CY181101327 T CY 181101327T CY 1121012 T1 CY1121012 T1 CY 1121012T1
Authority
CY
Cyprus
Prior art keywords
tapentadol
prevention
painting
treatment
pain
Prior art date
Application number
CY181101327T
Other languages
English (en)
Inventor
Klaus Schiene
Ilona Steigerwald
Michel Hamon
Johannes Schneider
Silvia Reinartz
Ulrich Jahnel
Thomas Tzschentke
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46025592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of CY1121012T1 publication Critical patent/CY1121012T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση αφορά ταπενταδόλη για χρήση στην αγωγή του πόνου σε ένα υποκείμενο που υποφέρει από χρονιοποίηση του πόνου και/ή στην αγωγή ή την πρόληψη της χρονιοποίησης του πόνου. Η εφεύρεση αφορά επίσης ταπενταδόλη για χρήση στην αγωγή ή την πρόληψη της ημικρανίας.
CY181101327T 2011-04-05 2018-12-11 Ταπενταδολη για την προληψη της χρονιοποιησης του πονου CY1121012T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11002811 2011-04-05
EP11003508 2011-04-29
PCT/EP2012/001472 WO2012136349A1 (en) 2011-04-05 2012-04-03 Tapentadol for preventing chronification of pain
EP12718064.4A EP2694049B1 (en) 2011-04-05 2012-04-03 Tapentadol for preventing chronification of pain

Publications (1)

Publication Number Publication Date
CY1121012T1 true CY1121012T1 (el) 2019-12-11

Family

ID=46025592

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101327T CY1121012T1 (el) 2011-04-05 2018-12-11 Ταπενταδολη για την προληψη της χρονιοποιησης του πονου

Country Status (13)

Country Link
US (3) US20120309841A1 (el)
EP (2) EP3449917A3 (el)
JP (3) JP2014510759A (el)
CY (1) CY1121012T1 (el)
DK (1) DK2694049T3 (el)
ES (1) ES2703282T3 (el)
HR (1) HRP20181998T1 (el)
LT (1) LT2694049T (el)
PL (1) PL2694049T3 (el)
PT (1) PT2694049T (el)
RS (1) RS58064B1 (el)
SI (1) SI2694049T1 (el)
WO (1) WO2012136349A1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2694049T3 (pl) 2011-04-05 2019-07-31 Grünenthal GmbH Tapentadol do zapobiegania przechodzeniu bólu w stan przewlekły
WO2012146383A1 (en) 2011-04-29 2012-11-01 Grünenthal GmbH Tapentadol for preventing and treating depression and anxiety
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
AU2021201351B1 (en) * 2020-11-10 2022-04-21 Grünenthal GmbH Dosage form providing prolonged release of a salt of Tapentadol with L-(+)-tartaric acid

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20070093420A1 (en) 2005-08-26 2007-04-26 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US20090306050A1 (en) 2006-02-03 2009-12-10 Timothy Dinan Treatment and prevention of depression with pain, depression secondary to pain, and of neuropathic pain
ES2358763T3 (es) * 2006-04-28 2011-05-13 Grünenthal GmbH Combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metilpropil)fenol y un nsaid.
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
KR101607112B1 (ko) * 2007-11-23 2016-03-29 그뤼넨탈 게엠베하 타펜타돌 조성물
EP2254577A1 (en) 2007-12-26 2010-12-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
US7868043B2 (en) 2008-01-25 2011-01-11 Xenoport, Inc. Mesophasic forms of (3S)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
ES2625949T3 (es) 2009-04-30 2017-07-21 Grünenthal GmbH Tapentadol para el tratamiento del dolor artrítico reumatoide
FR2970261B1 (fr) 2011-01-10 2013-05-03 IFP Energies Nouvelles Procede d'hydrotraitement de charges lourdes d'hydrocarbures avec des reacteurs permutables incluant au moins une etape de permutation progressive
PL2694049T3 (pl) 2011-04-05 2019-07-31 Grünenthal GmbH Tapentadol do zapobiegania przechodzeniu bólu w stan przewlekły

Also Published As

Publication number Publication date
LT2694049T (lt) 2018-12-27
JP2014510759A (ja) 2014-05-01
DK2694049T3 (da) 2019-01-02
US20120309841A1 (en) 2012-12-06
US20160354324A1 (en) 2016-12-08
SI2694049T1 (sl) 2019-01-31
JP2018048122A (ja) 2018-03-29
RS58064B1 (sr) 2019-02-28
HRP20181998T1 (hr) 2019-01-25
EP2694049B1 (en) 2018-10-31
JP6840057B2 (ja) 2021-03-10
US20200009083A1 (en) 2020-01-09
EP3449917A2 (en) 2019-03-06
PL2694049T3 (pl) 2019-07-31
ES2703282T3 (es) 2019-03-07
EP2694049A1 (en) 2014-02-12
US10398657B2 (en) 2019-09-03
EP3449917A3 (en) 2019-06-05
WO2012136349A1 (en) 2012-10-11
JP2019142932A (ja) 2019-08-29
US10813891B2 (en) 2020-10-27
PT2694049T (pt) 2019-02-06

Similar Documents

Publication Publication Date Title
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1125436T1 (el) Αναστολεις dna-pk
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1123470T1 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
CY1120929T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
CY1119533T1 (el) Νεοι θεραπευτικοι παραγοντες
CY1120506T1 (el) Θεραπευτικα δραστικες ενωσεις και μεθοδοι χρησης αυτων
CY1117678T1 (el) Ενωσεις αναστολεων μεταλλοενζυμου
CY1121012T1 (el) Ταπενταδολη για την προληψη της χρονιοποιησης του πονου
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
EA201391248A1 (ru) Биспецифические связывающие агенты
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
UY33863A (es) Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EA201370071A1 (ru) Способы и композиции для лечения рака легких
CA2871774C (en) Use of n-acetylcysteine amide in the treatment of disease and injury
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
CY1122998T1 (el) Μεθοδοι και συνθεσεις για την αντιμετωπιση της καταθλιψης χρησιμοποιωντας κυκλοβενζαπρινη
BR112015006705A2 (pt) antiandrogênios para o tratamento de câncer de próstata resistente à castração não metastático